Compare Amphastar Pharmaceuticals Inc (AMPH) vs General Dynamics Corporation (GD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs General Dynamics Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while General Dynamics Corporation trades at $375.48 (market cap $101.43B). The key difference: General Dynamics Corporation is far larger — about 122.8× Amphastar Pharmaceuticals Inc's market cap, and General Dynamics Corporation pays a 1.7% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | GD | |
|---|---|---|
Market Cap | $826.08M | $101.43B |
Sector | Health | Industrials |
52-Week High | $30.81 | $376.88 |
52-Week Low | $16.87 | $297.05 |
Enterprise Value | $1.22B | $107.61B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
General Dynamics (GD) trades at $375.06, up 0.12% today, near its 52-week high with strong technical momentum. The stock shows robust fundamentals, including consistent earnings beats, revenue growth to $52.55B in 2025, and healthy margins. Analyst sentiment is bullish, with a consensus price target of $395.83, supported by a backlog surge to $130.8B in Q1 2026 (Seeking Alpha, 2026-07-02).
Outlook remains positive due to defense spending tailwinds and submarine contract wins, but risks include execution delays and valuation concerns. The stock offers growth potential with a 5.6% upside to consensus target, though high RSI levels suggest near-term overbought conditions. Investors should weigh strong cash flow and dividend stability against geopolitical and supply chain uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
